Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis
Kenvue, a two-year-old spinoff from Johnson & Johnson, is confronting [...]
La empresa detrás de Tylenol intenta sortear su crisis más reciente
Kenvue, una empresa derivada de Johnson & Johnson, se enfrenta [...]
These Patients Got the Cure. Then It Went Away.
Gene therapies for rare diseases are frequently developed then discarded [...]
MapLight Therapeutics has…
MapLight Therapeutics has illuminated a path toward an initial public [...]
Angelini Pharma has worked out a…
Angelini Pharma has worked out a $550 million-plus biobucks deal [...]
Ionis Pharmaceuticals is eyeing a…
Ionis Pharmaceuticals is eyeing a new rare disease approval after [...]
Novo Nordisk’s Woes Are Slimming Denmark’s Economic Growth
Because of its size, the drugmaker has an outsize effect [...]
FDA OKs New Keytruda Shot for Cancer
The F.D.A. approved Merck’s injected version of its blockbuster infusion [...]
America’s Vaccine Future Is at a Crossroads
“We should be thinking that we’re heading for more damaging [...]
After a tumultuous journey filled…
After a tumultuous journey filled with delays and rejection, the [...]